Government’s new Health and Social Care Plan
Health and Social Care Secretary and Deputy Prime Minister, Thérèse [...]
Adjuvant pembrolizumab approved by NICE
Late last week we learnt that the National Institute for [...]
Telaglenastat plus cabozantinib in patients with metastatic kidney cancer
Cell metabolism in kidney cancer tumours is disrupted, and tumour [...]
ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer
The phase 2 KEYNOTE-B61 study was presented at the recent [...]
ESMO 2022: Update of the lenvatinib plus pembrolizumab versus sunitinib study in patients with advanced kidney cancer
Results from the phase 3 CLEAR studywere presented at the [...]
COVID-19 vaccines, boosters and immunity webinar
The National Core Studies Immunity (NCSi) Programme and UK Coronavirus Immunology Consortium (UK-CIC) are [...]
ESMO 2022: Atezolizumab as an adjuvant therapy
The results from the IMmotion010 study were presented at the [...]
ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer
In this phase 3 randomised study, presented at the European [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Northern Soul fundraising event
The second Northern Soul event took place over the weekend [...]
